Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

Leukemia Research

Volumn 28, Issue 7, 2004, Pages 679-689

  O'Farrell, Anne Marie ^a   Yuen, Helene A ^a   Smolich, Beverly ^a   Hannah, Alison L ^a   Louie, Sharianne G ^a   Hong, Weiru ^a   Stopeck, Alison T ^b   Silverman, Lewis R ^c   Lancet, Jeffrey E ^d   Karp, Judith E ^e   Albitar, Maher ^f   Cherrington, Julie M ^a   Giles, Francis J ^f  

^a SUGEN INC   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Angiogenesis; FLT3; KIT; Myelodysplastic syndrome; Refractory; SCF; SU5416; Tyrosine kinase inhibitors; VEGF

Indexed keywords

FLT3 LIGAND; SEMAXANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; IN VIVO STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REFRACTORY ANEMIA;

ACUTE DISEASE; ADULT; AGED; BONE MARROW; DOWN-REGULATION; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; LEUKEMIA, MYELOID; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; STEM CELL FACTOR;

EID: 2442584575     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.004     Document Type: Article

References (52)

1. Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 101:2003;1692-1697
2. Fiedler W., Mesters R., Tinnefeld H., et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 102:2003;2763-2767
3. Giles F.J., Cooper M.A., Silverman L., et al. Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer. 97:2003;1920-1928
4. Giles F.J., Stopeck A.T., Silverman L.R., et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 102:2003;795-801
5. Mendel D.B., Schreck R.E., West D.C., et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 6:2000;4848-4858
6. Sukbuntherng J., Cropp G., Hannah A., et al. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J. Pharm. Pharmacol. 53:2001;1629-1636
7. Fong T.A., Shawver L.K., Sun L., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106
8. Vajkoczy P., Menger M.D., Vollmar B., et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia. 1:1999;31-41
9. Shaheen R.M., Davis D.W., Liu W., et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:1999;5412-5416
10. Fenski R., Flesch K., Serve S., et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 108:2000;322-330
11. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 96:2000;3907-3914
12. Tse K.F., Mukherjee G., Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 14:2000;1766-1776
13. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 93:1999;3074-3080
14. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 10:1996;1911-1918
15. Rombouts W.J., Blokland I., Lowenberg B., et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 14:2000;675-683
16. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 98:2001;1752-1759
17. Yee K.W., O'Farrell A.M., Smolich B.D., et al. SU5416 and SU5614 inhibit kinase activity of wild type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2002;2941-2949
18. Ikeda H., Kanakura Y., Tamaki T., et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 78:1991;2962-2968
19. Kuriu A., Ikeda H., Kanakura Y., et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 78:1991;2834-2840
20. Sperling C., Schwartz S., Buchner T., et al. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica. 82:1997;617-621
21. Bene M.C., Bernier M., Casasnovas R.O., et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood. 92:1998;596-599
22. Meyer C., Drexler H.G. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines. Leuk. Lymphoma. 32:1999;577-581
23. Smolich B.D., Yuen H.A., West K.A., et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 97:2001;1413-1421
24. Fiedler W., Graeven U., Ergun S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 89:1997;1870-1875
25. Dias S., Hattori K., Zhu Z., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106:2000;511-521
26. Bellamy W.T., Richter L., Frutiger Y., et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:1999;728-733
27. Katoh O., Tauchi H., Kawaishi K., et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:1995;5687-5692
28. Giles F.J. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist. 6:2001;32-39
29. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 94:1999;3717-3721
30. Mesters R.M., Padro T., Bieker R., et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 98:2001;241-243
31. Gelderblom H., Verweij J., Nooter K., et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer. 37:2001;1590-1598
32. Michaud L.B. Methods for preventing reactions secondary to Cremophor EL. Ann. Pharmacother. 31:1997;1402-1404
33. Stopeck A., Sheldon M., Vahedian M., et al. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. 8:2002;2798-2805
34. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:2003;3597-3605
35. Jilani I., Estey E., Manshouri T., et al. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia. 17:2003;114-119
36. Estey E., Thall P., David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother. Pharmacol. 40:1997;S9-S12
37. Foran J., Paquette R., Cooper M., et al. A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy. Blood. 100:2002;558a. [abstract]
38. Smith B.D., Levis M., Brown P., et al. Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood. 100:2002;85a. [abstract]
39. Heinrich M.C., Druker B.J., Curtin P.T., et al. A "First in Man" study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia. Blood. 100:2002;336a. [abstract]
40. Stone R.M., Klimek V., DeAngelo D.J., et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial. Blood. 100:2002;86a. [abstract]
41. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 16:2003;16
42. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9:2003;327-337
43. Levis M., Allebach J., Tse K.F., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:2002;3885-3891
44. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443
45. Retzlaff S., Padro T., Koch P., et al. Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma. Oncol. Rep. 9:2002;525-527
46. Mosca P.J., Hobeika A.C., Colling K., et al. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J. Leukoc. Biol. 72:2002;546-553
47. Morse M.A., Nair S., Fernandez-Casal M., et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18:2000;3883-3893
48. Molldrem J. Immune therapy of AML. Cytotherapy. 4:2002;437-438
49. Molldrem J.J. Antigen-specific lymphocyte therapies. Cytotherapy. 4:2002;315-316
50. Cortelezzi A., Cattaneo C., Cristiani S., et al. Low plasma stem cell factor levels correlate with in vitro leukemic growth in myelodysplastic syndromes. Leuk. Res. 23:1999;271-275
51. Wu B., Feng R., Liu X.L., et al. Expression of stem cell factor mRNA in primary leukemia cells. Di Yi Jun Yi Da Xue Xue Bao. 21:2001;812-814
52. Murohashi I., Yoshida K., Kishimoto K., et al. Differential response to stem cell factor and Flt3 ligand by the FAB subtype in acute myeloid leukemia clonogenic cells. J. Interferon Cytokine Res. 22:2002;335-341